On an adjusted basis and at constant exchange rates, Q4 revenues increased about 3 percent year over year, but fell short of previously stated guidance of 5 percent growth.
For the quarter ended Sept. 30, Cepheid reported preliminary revenue of approximately $126.5 million, shy of the Wall Street estimate of $127.8 million.
In Science this week: approach to measure microRNA targeting efficiency, strategy to conduct high-throughput chemical screens at single-cell resolution, and more.